Sunday, November 1, 2026

How Terraform Labs Misled Thousands of Investors

The prosecution submitted to the court a...

Samsung Unveils 2026 Odyssey Lineup With Industry’s First 6K Gaming Monitor

Samsung Electronics launches four new Odyssey gaming monitors, including the first 6K model, enhancing the premium gaming experience.

Samsung Shares Surge: What to Expect from Q3 Earnings and Shareholder Returns?

Samsung Group stocks surge ahead of Samsung Electronics' Q3 earnings report, fueled by SK Hynix's record performance and shareholder return plans.

Health

Unlock Your Health: Discover the New AI-Powered BioAge and Health Coach Services from DaNaA Data

Daewoo Group's AI health data firm, DaNaA Data, launched a service analyzing biological age, disease risk, and health check results.

How the New Medical School in Namwon Can Transform Regional Healthcare: Insights from Lawmaker Park Ji-won

Defining school locations alone won't solve local healthcare issues; deeper strategies are needed for effective solutions.

Ardens Lifescience Triumphs: How a Korean Startup Won 175,000 USD at MedTech Innovator APAC 2026

Adenz Life Sciences wins a global medical device competition, earning a prize of 175,000 USD.

Unlocking the Future of Healthcare: Daewoong’s AI-Powered Smart Hospital at AI EXPO MARS 2026

Daewoong Pharmaceutical introduces an AI-based smart hospital model for monitoring, diagnosis, testing, and rehabilitation.

10 Years of Excellence: Seoul’s APLAR Center Hosts International Rheumatology Training for Young Specialists

Seoul St. Mary's Hospital's Rheumatology Center held an international training program for foreign experts on October 27 and 26.
Latest

Revolutionizing Healthcare: How Low-Risk NK Cell Therapy is Changing Regenerative Medicine in 2026

The Ministry of Health reclassifies autologous immune cell cultivation as low risk, expediting treatment access while ensuring safety.

Lotte Biologics says it has secured top-10 global CDMO manufacturing capacity [BIO USA]

Lotte Biologics is set to begin commercial production by the end of 2026, advancing its capabilities in the global CDMO market.

ABL Bio to Launch Global Phase 3 Trial of Gastric Cancer Drug Givastomig This Year at BIO USA

ABL Bio plans a Phase 3 trial for gastric cancer therapy Givastomig, targeting a $2.5 billion market opportunity.

NVP Healthcare Signs Exclusive Supply Deal for NVP-1702 With Brazil’s Marjan Farma at BIO USA

NVP Healthcare signs a deal with Marjan Farma to supply its probiotic NVP-1702 for liver health products in Brazil, aiming for market expansion.

Shaperon to Expand Biobeauty Business With NeedsTech, Targeting Hong Kong, Taiwan and U.S. Markets

Shaperon is acquiring NeedsTech to enhance its biobeauty business and expand globally, targeting markets in Hong Kong, Taiwan, and the U.S.

From Keycaps to World Cup Matches, K-Bio Turns BIO USA Into a Marketing Showcase

The BIO International Convention 2026 showcased innovative marketing and cultural engagement, enhancing the biotech industry's global appeal.

Is BTGEN the Next Big Player in Biopharmaceuticals? Discover Their Unique CDMO Strategy

BTGEN is expanding its CDMO business with National Growth Fund support, focusing on innovative processes instead of competing on scale.

K-Bio’s Global Leap: How Korea’s Biotech is Shaping Asia’s Innovation Hub

The BIO USA 2026 highlighted Korea's biotech growth, emphasizing the need for increased capital to enhance global competitiveness.

K-Beauty Shines at BIO USA 2026: Discover the Future of Bio-Integrated Skincare!

K-Beauty showcased its biotech innovations at BIO USA 2026 with a pop-up store, attracting global attention and business opportunities.

Samsung Biologics Expands Global Reach: New European Sales Office Set to Boost Biopharmaceuticals Market

Samsung Biologics expands its global sales network with a new office in Europe, aiming for growth in production and portfolio diversification.

Gilead Launches CAR-T Therapy Yescarta in Korea, Offering Fourfold Survival Benefit for Relapsed or Refractory Lymphoma Patients

Yescarta is widely used for second-line treatment in patients with very low survival rates, and should be adopted as a standard treatment in Korea.

ST Pharm Targets Next-Generation RNA Therapies, Positions Itself as Key CDMO Partner at BIO USA

The RNA therapeutics market is evolving, with ST Pharm aiming to lead in precision manufacturing and targeted delivery for next-gen therapies.

“Cheers” in San Diego: K-Biopharma Showcases Growing Global Influence at BIO USA Networking Event

KPBMA supports Korean pharma's global expansion at BIO USA, boosting international interest and partnerships in the biotech sector.

Korean Biopharma Takes Center Stage at BIO USA as Industry Giants and Biotechs Expand Global Reach

The BIO USA 2026 convention gathers over 20,000 bio industry professionals, highlighting the growing presence of Korean companies.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.